Phase One · four labs

Build the evidence, then test it before you fund anything against it.

Five to six weeks, fixed fee, fixed scope. Four labs that read your own deal history into something an agent can run, and a live market test inside the engagement rather than after it.

5 to 6 weeksKickoff to a documented plan
$14k to $22kFixed fee, fixed scope
Four labsICP, Message, Channel, Signal
Yours to keepWith us or without us

Rather watch than read? The whole thing in a minute and a half: ten scenes, no sound, the script printed underneath.

Where you are now

Four failure modes, and almost every company we meet has at least two of them running at once.

01
The ICP is a guess
Targeting built on who answered the phone last quarter, not on who converts, expands and renews.
02
The plan was never written down
No documented motion, so every new hire reinvents the pitch and every campaign starts from zero.
03
Hiring is the only lever
Ramp is six to nine months and the cost lands before the first qualified meeting does, assuming the hire was right.
04
Tools got bought, not built into a system
A stack nobody owns end to end, producing activity metrics instead of pipeline.

What it costs to leave it

Trial and error is the most expensive way to learn something you could have known in six weeks. The bill does not arrive as a line item. It arrives as a quarter of headcount pointed at a segment that was never going to buy, a sending domain you cannot use any more, and a team that has stopped believing the targeting.

The reason it keeps happening is structural. Most go-to-market plans are reasoned internally and tested nowhere. First contact with reality happens after the budget and the headcount are already committed, which is the one point at which nobody wants to hear that the premise was wrong.

A strategy that has never met the market is a hypothesis with a price tag.

What we do about it

A lab is where you test something before you scale it. Phase One is four of them, run in sequence. Each produces an output you own outright, and the fourth decides whether the first three were right.

Lab 01 · ICP
Who actually buys
Closed-won, closed-lost, churn and expansion read for economic pattern rather than demographic convenience. Segmented on deal velocity, contract value and retention, not on company size and industry. You end with firmographics, triggers, disqualifiers and buying-committee roles, written down.
Lab 02 · Message
What makes them care
A value argument per segment, mapped to proof points you can stand behind, rather than one deck for everyone. What you say, to whom, and why it matters to them specifically.
Lab 03 · Channel
How you reach enough of them
The motions that work economically at your contract value, the sales motion documented with stages and qualification criteria, and the handful of numbers that predict revenue separated from the ones that only look like progress.
Lab 04 · Signal
What the market says back
Real outreach to real accounts inside your segments. Not a survey, not a panel. Reply rates by segment and by message, the objections that recur, and the segments that stayed silent.

Most strategy work stops at three. The fourth lab is the difference the whole model rests on.

Five segment hypotheses, from Labs 1 to 3
SEG 01
Specialty distribution
Replies
SEG 02
Managed IT, 50 to 200 seats
Silence
SEG 03
Insurance brokerages
Replies
SEG 04
Regional staffing
Silence
SEG 05
Light manufacturing
Silence

Segment names are illustrative. Silence is a result, and it is the expensive one to learn later. Only what produced signal carries into execution, which is the whole reason the test sits inside the engagement rather than after it.

You typically finish Phase One with first conversations already in motion rather than a document and an assumption. Then the lab closes. Phase two is production, not experimentation. The risk gets taken on our time, inside Phase One, before it gets taken on your budget.

Why not just use software to build the ICP?

It is a fair question and a real product. Connect your CRM, the system reads your closed-won deals, finds what the winners have in common, and writes you a profile by the afternoon. The math is not fake. The problem is the training set: it is your own history.

In your system
Every account your team pursued.
In nobody's system
The four hundred you looked at and decided not to call, and why.
In your system
Closed Won. $50,000. Manufacturing.
In nobody's system
That their ops director had worked with you somewhere else, which is the difference between a segment and one relationship.
In your system
Pipeline created, stage by stage.
In nobody's system
How many live conversations your team can actually carry before quality falls off.

An ICP derived from your CRM can only recommend more of what you already chose. If those choices were right, you did not need the exercise. If they were wrong, the software reproduces the error confidently, at scale, and calls it a finding. Phase One asks the questions that leave no trace in a database, checks every answer against the deals you actually won, and then tests the result in the market before anyone builds an outbound motion on top of it.

Where this argument stops, since we would rather say it than have you find it. If you have thousands of clean closed-won records and a RevOps function maintaining them, fitting a model to that history is reasonable and you should do it. Most companies we work with have fewer than a hundred, entered by sellers in a hurry, in a system nobody has audited since the last migration. At that size the model is not reading your market, it is reading your sales manager from three years ago. Longer version in the field notes.

The motion, worked through

What the first 180 days look like when Phase One runs into execution. Phase One itself is the first block, and it stands alone.

Days 1 to 30
Foundation
ICP derived from your own closed-won data, positioning built per segment, channel strategy set, and the plan documented and handed to you.
Days 31 to 90
Engine live
Platforms configured against the plan, campaigns launched, message tracks in live testing, and the first qualified appointments landing on a calendar.
Days 91 to 180
First revenue
First deals closed, messaging refined against real market response, and unit economics validated in your market rather than assumed.
Months 6 to 12
Scale
Segments expanded, cross-sell plays running against accounts you already own, and output scaling without linear cost.

How Outpace works

Assessment first, execution second. You are not signing a long engagement on day one. You are buying a short, defined piece of work that either proves itself or does not.

$14,000 to $22,000

Fixed fee. Five to six weeks. Nothing further is owed if you stop here, and the output is yours either way. Execution is scoped afterwards, because pricing it before we have seen your data would be a guess.

If we are not the right partner for execution, you still walk away with a plan worth having. That is not generosity, it is the only structure under which a recommendation can be honest: saying no costs us the next engagement rather than the whole relationship.

What moves the price, and what it does not cover →

Three ways to start

No cost
Evidence Check
25 accounts, account and contact drift only, one page back to you. Deliberately small. Usually enough to tell you whether anything here is worth your time.
Free
Recommended
Evidence Review
Ten business days. Five weighted dimensions scored against your own data, with a verdict on whether your targeting is safe to automate yet.
$3,500, credited toward Phase One
The full build
Phase One
Four labs, five to six weeks, with a live market test inside the engagement. Rebuilds the layer your agents run on.
$14k to $22k

Pricing and timelines are engagement terms, not client results. Outpace Labs is early, and we would rather publish what we can be held to now than numbers we cannot attribute.

Not sure which of the three you need?

Thirty minutes, no deck. If the honest answer is that you do not need us yet, we will tell you that and you will have lost half an hour.

← Back to the diagnostic